Mike brings over 20 years of experience in drug discovery. He joined IDEAYA Biosciences as Senior Vice President, Head of Drug Discovery in April 2016, and has served as Senior Vice President and Chief Scientific Officer, Head of Research since February 2018. From 2008 to 2016, Mike was with the Novartis Institutes for Biomedical Research (NIBR) where he served in various leadership roles, including Global Discovery Chemistry Head, Oncology and New Therapeutic Modalities; Head of Chemical Sciences, Emeryville, and Executive Director Oncology Chemistry. Under his leadership at NIBR, several small molecules were advanced towards the clinic, including, PI3K inhibitor BKM120, CSF1R inhibitor BLZ945, V600E mutant B-RAF kinase inhibitor Encorafenib, PIM kinase inhibitor PIM447, ERK inhibitor LTT462, and RAF kinase inhibitor LXH254. From 1993 to 2008, Mike worked at Roche and Syntex (acquired by Roche), where he served in roles of increasing responsibility, including Director, Medicinal Chemistry. At Roche, he led multiple small molecule programs that advanced to the clinic, including first-in-class P2X3 antagonist Gefapixant, now being developed by Merck. Mike is an author on over 60 publications and patents.
Mike obtained his B.Sc. (Hons) from the University of Leicester, and his Ph.D. in Chemistry from the University of Bristol. He completed his postdoctoral fellowship at Oregon State University to continue his research in Chemistry with Professor James D. White.
What is Michael P. Dillon's net worth?
The estimated net worth of Michael P. Dillon is at least $2.93 million as of September 7th, 2021. Mr. Dillon owns 78,905 shares of IDEAYA Biosciences stock worth more than $2,929,743 as of April 19th. This net worth estimate does not reflect any other investments that Mr. Dillon may own. Learn More about Michael P. Dillon's net worth.
How do I contact Michael P. Dillon?
Has Michael P. Dillon been buying or selling shares of IDEAYA Biosciences?
Michael P. Dillon has not been actively trading shares of IDEAYA Biosciences over the course of the past ninety days. Most recently, Michael P. Dillon sold 1,500 shares of the business's stock in a transaction on Monday, October 4th. The shares were sold at an average price of $26.36, for a transaction totalling $39,540.00. Learn More on Michael P. Dillon's trading history.
Who are IDEAYA Biosciences' active insiders?
Are insiders buying or selling shares of IDEAYA Biosciences?
In the last twelve months, insiders at the sold shares 21 times. They sold a total of 219,474 shares worth more than $8,035,837.19. The most recent insider tranaction occured on February, 9th when CEO Yujiro S Hata sold 23,557 shares worth more than $1,072,785.78. Insiders at IDEAYA Biosciences own 5.1% of the company.
Learn More about insider trades at IDEAYA Biosciences. Information on this page was last updated on 2/9/2024.
